In a patient with diarrhea, a positive Clostridioides difficile antigen test but negative toxin assay, what are the next steps in management?

Management of GDH-Positive, Toxin-Negative Clostridioides difficile Testing

In a patient with diarrhea who tests positive for C. difficile antigen (GDH) but negative for toxin, you should perform nucleic acid amplification testing (NAAT/PCR) to arbitrate the result and guide treatment decisions based on clinical pretest probability.

Diagnostic Algorithm

The GDH-positive/toxin-negative result represents an indeterminate finding that requires further testing 1. This two-step approach is specifically recommended by IDSA/SHEA guidelines to increase positive predictive value compared to single-step testing 1.

Next Steps:

1. Order NAAT (PCR) testing immediately to determine if toxigenic C. difficile is present

   • Research shows 63-91% of GDH-positive/toxin-negative patients harbor toxigenic strains 2, 3
   • PCR has 93.3% sensitivity compared to toxin EIA's 73.3% 1

2. Assess clinical pretest probability while awaiting PCR results:

   • High pretest probability indicators:
     • ≥3 unformed stools in ≤24 hours
     • Recent antibiotic exposure
     • Fever present
     • Healthcare facility exposure
   • Studies demonstrate that only 11% of low pretest probability patients have positive toxin results versus 63% of high pretest probability patients 4

Treatment Decision Framework

Do not initiate empiric treatment based solely on GDH-positive/toxin-negative results 1. The management depends on:

If PCR is Positive:

• Treat as CDI if clinically symptomatic with appropriate pretest probability
• Berry et al found 91.5% of PCR-positive/toxin-negative patients were clinically diagnosed with CDI 1
• Patients who are toxin-negative but PCR-positive have lower 30-day mortality than toxin-positive patients 1

If PCR is Negative:

• Do not treat for CDI
• Pursue alternative diagnoses (antibiotic-associated diarrhea, chemotherapy-related diarrhea, other infectious causes) 5

If High Clinical Suspicion Despite Negative Testing:

• Consider repeat testing only if clinical presentation changes or symptoms worsen 1
• Do NOT perform routine repeat testing within 7 days (diagnostic yield only ~2%) 1

Critical Pitfalls to Avoid

1. Do not treat empirically without confirmatory testing - Up to 64% of GDH-positive/toxin-negative patients receive unnecessary treatment 4, which can harm microbiome restoration

2. Do not repeat testing to document cure - Over 60% of successfully treated patients remain C. difficile positive 1

3. Consider false-negative toxin results in specific contexts:

   • High-dose corticosteroid therapy can cause false-negative toxin results 6
   • Lower body mass index patients may have higher rates of toxigenic strains despite negative toxin 2

4. In IBD patients with GDH-positive/toxin-negative results:

   • Recent evidence suggests antibiotic treatment may worsen IBD outcomes 7
   • Focus on IBD management rather than empiric CDI treatment unless PCR confirms toxigenic strain 7

Special Considerations

If oral therapy is not feasible (due to nausea/vomiting), intravenous metronidazole can be used temporarily, though this is suboptimal compared to oral fidaxomicin or vancomycin 6.

The key principle is that GDH detects the organism's presence (colonization or infection), while toxin and PCR help distinguish true infection from colonization 1. Clinical context combined with PCR arbitration provides the most accurate diagnosis for treatment decisions.